Semaglutide 2.4 mg (Wegovy):A Turning Point for Obesity

Jun 25, 2021, 01:26 PM

Ahead of ADA 2021, Dr. Thomas Wadden discusses the significance of the Wegovy approval for chronic weight management and Novo Nordisk's plans to evaluate an oral version. 
Subscribe
Next
Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives
Top Episodes